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Abstract
Purpose of Review To collate the best evidence from several strands—epidemiological, genetic, comparison with historical data
and mechanistic information—and ask whether obesity is an important causal and potentially modifiable risk factor for severe
COVID-19 outcomes.
Recent Findings Several hundred studies provide powerful evidence that body mass index (BMI) is a strong linear risk factor for
severe COVID-19 outcomes, with recent studies suggesting ~5-10% higher risk for COVID-19 hospitalisation per every kg/m2
higher BMI. Genetic data concur with hazard ratios increasing by 14% per every kg/m2 higher BMI. BMI to COVID-19 links
differ markedly from prior BMI-infection associations and are further supported as likely causal by multiple biologically
plausible pathways.
Summary Excess adiposity appears to be an important, modifiable risk factor for adverse COVID-19 outcomes across all
ethnicities. The pandemic is also worsening obesity levels. It is imperative that medical systems worldwide meet this challenge
by upscaling investments in obesity prevention and treatments.
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Evidence for Obesity as a Risk Factor
for Severe COVID-19
This paper first discusses the range of evidence implicating
obesity as a causal risk factor for adverse COVID-19-related
outcomes (summarised Table 1). It then discusses why such
evidence, when added to widening appreciation of the adverse
impacts of obesity on many chronic conditions, as well as the
impacts of lockdown on body mass index (BMI) levels,
should stimulate relevant health systems to upscale efforts
on obesity prevention and management.
Epidemiology
There is now overwhelming evidence that BMI relates linearly
to adverse COVID-19 outcomes. A quick literature search on
BMI and COVID comes up with over 500 papers, and though
many are of suboptimal quality, there is a consistent finding of
higher BMI being associated with worse COVID-19 out-
comes. Some of the best data comes from larger nationwide
cohort studies. For example, the OpenSAFELY study of over
17 million adults in England, showed that a body mass index
(BMI) of over 40 to be associated with a near doubling [HR
1.92 (1.72–2.13)] of death from COVID-19 compared to peo-
ple who were not living with obesity in a model adjusted for
confounders [1]. In UK biobank studies, whilst not nationally
representative, we showed that BMI, measured around a de-
cade before the pandemic began, which has its advantages as
BMI measured when younger is more likely to be accurate
and relate to adverse outcomes [2], was linearly associated
with higher risk for hospitalisation and death from COVID-
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19 [3•]. Moreover, associations between BMI and adverse
COVID-19 outcomes appeared stronger in younger people
and those of non-white ethnicity [3•]. This latter finding was
recently extended by Jebb and colleagues in a recent analysis
of QResearch data with almost sevenmillion people [4••]. The
authors demonstrated a linear increase in risk beyond a BMI
of 23 kg/m2 with hospitalisation risk increasing by an HR
(adjusted) of 1.05 [95% CI 1.05–1.05]) per kg/m2. Once
again, associations were stronger in younger people, but in
this case, risks were higher in those of Black ethnicity. In
South Asians, the data also showed higher risks for death
and hospitalisation per unit increase in BMI but, perhaps due
to lack of power, not significantly so. Indeed, the study was
limited by BMI availability in routine health care, which is by
no means comprehensive, resulting in lower power in some
ethnic groups.
The wealth of evidence is such that more than a dozen
meta-analyses have been conducted on this topic, for ex-
ample [5, 6]. The reported levels of risk, however, vary
somewha t be tween s t ud i e s a s d i f f e r i ng s t udy
populations—population based versus hospital based—
can lead to differing findings with the latter being less
informative of risks in the general population as patients
in hospital with COVID represent a high-risk group with
more severe manifestations, and decisions to admit to hos-
pital are influenced by varying, often health system specif-
ic, factors. In addition, differing choices of the referent
BMI category, varying adjustment models and outcomes,
plus other discrepancies in methods, means it is not always
possible to compare BMI-to-COVID risk levels between
studies. Even so, the totality of evidence supports higher
BMI being associated with a greater chance of SARS-
CoV2 infection, greater likelihood of hospital admission
and greater need for mechanical ventilation and mortality
from COVID-19. The evidence, where available in specific
subgroups such as those with diabetes [7], suggests BMI
may be more strongly linked to COVID-19 mortality than
mortality from other causes, an important observation
which further highlights the strength of the link between
obesity and COVID-19. As such, if elevated BMI is caus-
ally related to adverse outcomes, it represents a key mod-
ifiable pre-infection risk factor to lessen chances of devel-
oping severe COVID-19.
Genetics
Given the potential for confounding in observational stud-
ies and the problem with BMI in the set t ing of
multimorbidity—BMI is often lowered in many conditions
due to reverse causality—additional evidence is needed to
support BMI as causal for adverse COVID-19 outcomes.
Mendelian randomisation (MR) is one such method. It ex-
ploits genes randomly allocated at conception which leads
Table 1 A summary of the range of evidence linking obesity to adverse COVID-19 outcomes following SARS-CoV2 infection
Current evidence Future research ideas
Epidemiological Multiple studies—of varying veracity—show higher BMI broadly
linearly linked to worse COVID-19 outcomes, including at
least a dozen meta-analyses. Where examined, links between
BMI and mortality are stronger than links between BMI and
non-COVID-related mortality, as well as far stronger than prior
links between BMI and influenza or adult respiratory distress
syndrome (ARDS).
More evidence of links of differing adiposity measures to
COVID-19 would be useful.
Genetic A recent Mendelian randomisation study in those of European
Ancestry found obesity to be a likely causal risk factor with a
14% (95% CI 7 to 21%) higher risk for hospitalisation due to
COVID-19 per every 1kg/m2 higher BMI. No other causal risk
factors were identified though more power needed in future
studies.
Validation of these genetics’ findings will come soon and should
expand to other measures of adiposity and in differing ethnic
groups.
Interventions There are no trials as such, but a retrospective bariatric surgery
analysis suggests people who lose (around 12 BMI units)
weight through bariatric surgery are at 69% lower risk of
hospitalisation and lower risk for ICU admission than
pre-surgery BMI-comparable people who had not undergone
surgery.
It remains unclear whether formal trials of weight loss can be large
enough to prove intentional weight loss protects against
adverse COVID-19 outcomes.
However, it may be possible that randomised trials of weight
loss-promoting drugs, if enough people in trials did develop
COVID-19 and robust outcome data were recorded,
could prove the weight loss theory.
Biological
plausibility
Obesity contributes to metabolic derangements, worse lung and
kidney function, poorer vascular health, and is associated with a
low-grade inflammation and a greater thrombogenic potential.
In this way, obesity lessens an individual’s capacity to cope
with the systemic effects of the hyperimmune response.
Understanding how excess fat stores or adipose tissue impairs
the immune response, in general and in COVID-19, requires
dedicated research
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people to have lifelong lower or higher BMI levels. By
examining these genes and relating them to long term out-
comes, a more informed causal case between excess weight
and disease outcomes can be made. Such methods have
been used to support higher BMI as a causal risk factor
for multiple cardiovascular outcomes (e.g., coronary heart
disease, atrial fibrillation and heart failure) [8•], and many
other diseases. Using this MR approach, Leong and col-
leagues related genetics that underpin 17 cardiometabolic
traits to risk for COVID-19 outcomes [9••]. The only sta-
tistically positive association was for genes that predict
higher BMI—a 14% (95% CI 7 to 21%) higher risk for
COVID-19 hospitalisation per every 1kg/m2 higher BMI
level was noted, a risk around twice seen in observational
studies. Such risk seemed to be explained in part by the
downstream links of BMI to several conditions including
type 2 diabetes, chronic kidney disease, coronary artery
disease and stroke, which makes sense as obesity is a caus-
al risk factor for such conditions. These MR data, conduct-
ed in those with European ancestry, therefore add strong
support for elevated BMI being causally related to
COVID-19 severity, and perhaps at a magnitude that is a
little stronger than suggested by observational data.
However, further genetic data are needed to validate find-
ings and, to extend analyses to other ethnicities and to
examine whether other measures of adiposity have similar
or potentially stronger links to COVID-19 mortality.
Interventions
Given that the pandemic began just over a year ago, it would
be unrealistic to expect adequately powered randomised trials
of weight loss to have been conducted to prove weight loss
leads to lower risks for severe COVID-19. However, indirect
findings from patients before and after bariatric surgery are
notable. Aminian and colleagues identified 33 patients in their
records with prior bariatric surgery who had tested positive for
SARS-CoV-2 and matched them to 330 people who had a
BMI ≥40 kg/m2 at the time of a positive viral test but who
had not undergone surgery [10]. The surgery patients had a
BMI near 49 kg/m2 before surgery which went down to
around 37 kg/m2 at the time of SARS-CoV-2 testing, whereas
the controls had a BMI of around 46 kg/m2. The authors
reported the surgery group to have around a 69% (95% CI
12-89%) lower risk for admission to hospital compared to
the controls. Also, none in the surgery group required ICU
admission, whereas 13% of the control population did.
Admittedly, this observational analysis had the usual limita-
tions of such research but, even so, it does suggest intentional
weight loss may lessen risks of severe COVID-19 in those
people living with severe obesity, an important observation
since, as described below, social factors may also put heavier
people at risk of COVID-19 infection. Whether smaller
amounts of intentional weight loss benefit others across the
adiposity spectrum remains to be proven.
Mechanisms
The potential mechanisms that link obesity to higher risk for
COVID-19 severity are likely to be multiple-fold, as we re-
cently reviewed [11••]. First, given the known association
between obesity and socioeconomic status, there is a greater
risk for people livingwith obesity being infected in the context
of multiple-person households; and people who are heavier
exhale substantially more virus as they breathe out [12•].
Secondly, once infected, the chances of experiencing the sec-
ond phase hyperimmune response, responsible for severe dis-
ease, may also depend on carrying relative more fat tissue as
there may be a critical interplay between adipose tissue and
immunity as fat cells can liberate multiple inflammatory pro-
teins. This latter suggestion is speculative, however, and re-
quires further research. Finally, as obesity contributes to met-
abolic derangements (linked in turn to ectopic fat in the liver
and pancreas), poorer vascular health, and greater thrombotic
potential, and can also adversely impact lung and renal func-
tion, people living with obesity have far less buffering capac-
ity against the systemic effects of the hyperimmune response
[11••]. There may also be indirect links between obesity and
COVID-19 outcomes such as an adverse diet-induced
microbiome impact on immune efficiency.
Evidence Comparing Risk Patterns
for COVID-19 Mortality to Those
from Historical Observations
It is notable that the link between type 2 diabetes and mortality
risk from COVID-19 is particularly strong, as reported in sev-
eral studies. Where examined, this diabetes to COVID-19
mortality link is also meaningfully stronger than comparable
risks in people with existing cardiovascular conditions [13],
which is notable as one would normally have anticipated life
years lost from diabetes to be like people with existing cardio-
vascular conditions [14]. As obesity is a much stronger up-
stream risk factor for type 2 diabetes than for cardiovascular
conditions, and as type 2 diabetes can be prevented or remis-
sion achieved by rapid weight changes, weight changes could
lessen COVID-19 risks by preventing some from converting
to diabetes. Even if glycaemia levels do not change, intention-
al weight loss is well known to favourably impact blood pres-
sure and lipid levels as well as cardiorespiratory fitness, plus
partially reverse many of the other pathways discussed above.
These findings suggests that any lifestyle improvements to
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lessen weight intentionally could protect people from a more
severe outcome should they contract SARS-CoV-2.
At the same time, and as also nicely summarised by Jebb
and colleagues in their recent paper [4••], prior work on sea-
sonal influenza infection in the USA showed that obesity
(BMI ≥30 kg/m2) is not a risk factor for requiring mechanical
ventilation or death [15]. Furthermore, there is no clear evi-
dence from a meta-analysis of over 6000 patients that obesity
was associated with higher mortality in patients admitted to
the ICU with adult respiratory distress syndrome [16]. These
findings suggest that excess weight has a specific association
with risk in people admitted with COVID-19, which may be a
function of the hyperimmune response that stresses the body
in a manner quite distinct to influenza or related conditions.
Directions for Future Research
Given the wealth of evidence linking BMI to adverse COVID-
19 outcomes, further epidemiological research would usefully
examine adiposity-COVID links across differing ethnicities
(Table 1). Further work examining whether measures of cen-
tral adiposity (i.e., waist or waist to hip ratio) give better esti-
mates of risks of excess (regional) adiposity from COVID-19,
would also be useful. Additional genetic data to validate early
findings from Leong and colleagues [9••] would also be valu-
able, including extending results to differing ethnic groups
and to genetic variants linked to measures of body fat distri-
bution. With respect to interventions, it is unlikely that a
weight loss trial can be adequately powered or sufficiently
large enough to prove benefits of intentional weight loss on
COVID-19 risks. It is also unlikely that ongoing trials of novel
weight losing drugs have sufficient power to show benefits of
drug-induced weight loss on COVID-19 outcomes but, even
so, such data would be of interest. Finally, as this COVID-19
pandemic has shone a light on potential links between excess
fat and immune function, more research examining such links
at a molecular level would be valuable (Table 1).
The Urgent Case for Better Obesity
Prevention and Management
Why Now?
If ever there was a time to discuss obesity management more
widely, it is now. The COVID-19 pandemic has shone a light
on obesity in an apparent new way—i.e., as a risk factor for an
acute infectious condition that has killed more than 3 million
people worldwide as well as contributing to many experienc-
ing long COVID. Whilst we know that people who are living
with overweight or obesity tend to do worse with some infec-
tions, the new COVID-19-obesity data, allied to an increasing
appreciation of the role of obesity in many chronic conditions,
presents a real opportunity to bolster the prevention and man-
agement of obesity (Figure 1). It should also be noted that
obesity is also a major risk factor for multimorbidity.
Survival rates from many obesity-related conditions have im-
proved, due to better medicines and interventions that lessen
mortality risks but do not necessarily lessen weights or lessen
associated morbidity. This means more people are living lon-
ger with their obesity and so can develop multiple obesity-
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Fig. 1 Obesity and COVID-19. Evidence from multiple sources now
links excess adiposity to risk for severe COVID-19 outcomes.
Additionally, many conditions associated with adverse COVID-19
outcomes (e.g. type 2 diabetes, COPD) are also strongly linked to
excess adiposity. At the same time, the pandemic and related
lockdowns and changes in life circumstances are accelerating weight
gain in many in the population. All of these facts means that
governments around the world, and particularly in countries where
obesity levels are already high, need to prioritise obesity prevention and
management efforts. The consequences of not doing so will be high for
both people and economies
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Pandemic Has Likely Worsened Obesity
Levels
The indirect consequences of the pandemic have paradoxical-
ly, made the situation even worse as more people have wors-
ened than improved their diets [17], and less people are as
active as they were pre-pandemic, linked to more working
from home, so less active travel, as well as anxieties in many
individuals in spending time outdoors. There is emerging ev-
idence to suggest pandemic-associated weight gain, potential-
ly more marked in younger people, in women compared to
men, and in people from more deprived communities [18•,
19].
Roles for National Governments, Local
Governments, and Health Care Systems
So, what can be done? Debate has often focussed on the rel-
ative merits of population-level vs. individual-level interven-
tions, the former associated with large reach and very small
cost and impact per individual, and the latter associated with
more limited reach and higher cost and impact per individual.
We would argue that both approaches have merit and should
be embraced—any single approach is likely to only carry a
small effect size, and so we need as many different policies as
possible in our portfolio of actions to make an appreciable
difference. Population-level interventions often fall within
the remit of national and local governments, with respective
examples: levies on sugar sweetened beverages [20]; and local
controls over establishing unhealthy food outlets near schools
[21]. Individual-level interventions are often embedded in
health care systems, involving facilitated access for individ-
uals to interventions supporting the achievement of a healthy
weight [22].
Recent announcements by the UK Government are consis-
tent with this broad portfolio of actions, involving both
population-level and individual-level interventions [23, 24].
This includes proposals: to ban television and online adverts
for food high in fat, sugar and salt before 9pm; to end deals
like ‘buy one get one free’ on unhealthy food high in salt,
sugar and fat; to cause calories to be displayed on menus to
help people make healthier choices when eating out; to ensure
that alcoholic drinks have to list hidden ‘liquid calories’; to
provide significant additional investment to support individ-
uals—children, adults and families—achieve and maintain a
healthier weight. Ongoing evaluation of the impact of such
policies would be important to determine whether more needs
be done.
At the clinical level, more can be done to tackle obesity,
which is upstream of many conditions. However, whilst
most clinicians are adept at tackling its downstream conse-
quences, few have the expertise to help their patients
change their weight trajectories, and most rarely try, as
they believe any such advice will inevitably fail. Yet, the
evidence-based methods to help weight loss have im-
proved over the last decade. For example, based on
randomised trials [25], we know now that referral to com-
mercial weight loss programmes can help many achieve
meaningful weight loss, although uptakes need to improve,
particularly in men who are usually at higher obesity-
associated risks for many conditions, including COVID-
19. However, there is more evidence to suggest that weight
loss interventions implemented through national policy,
with referral pathways involving General Practice, have
the potential to overcome such inequities of access, across
the dimensions of gender, ethnicity, and socioeconomic
status [22, 26]. We also know that low calorie diets can
help some shed many kilograms rapidly with the potential
to achieve remission of diseases, such as type 2 diabetes
[27].
There are now also better medications to help achieve
meaningful weight loss (~10kg or more [28, 29]) and, though
expensive, we may be at the start of an era where substantial
weight loss is achievable by pharmacotherapy, in a manner
that appears safe and hopefully lessens risks for obesity-
related outcomes. Evidence from trials completing in the next
few years, e.g. SURPASS [30] and SELECT [31], is eagerly
anticipated. Also, bariatric surgery has its place for some pa-
tients living with obesity and comorbidities as it can transform
and extend lives, and substantially reduce the risk of future
complications, including cardiovascular disease, cancers, kid-
ney disease and heart failure [32, 33].
Gaps in Practice?
Despite all the above interventions, many people living with
obesity or obesity-related comorbidities are falling through the
net and, presently, only a minority are supported to achieve a
healthier weight. Many are also not at the stage where they are
willing to consider referral to outside agencies, and even
though newer drugs for weight loss are coming, they are ex-
pensive, at different stages of licensing, and when they are
stopped, most people put weight back on. Hence, we need to
think outside the box and extent our current armamentarium to
tackle obesity.
The National Health Service (NHS) in England has recent-
ly published intentions and started implementation to deliver
new or expanded services: to provide a targeted support offer
and access to weight management services for people with a
diagnosis of diabetes or hypertension and living with a BMI in
the obese range (adjusted appropriately for ethnicity); dou-
bling of the capacity of the NHS Diabetes Prevention
Programme to support participation of 200,000 individuals
per year by 2024 [22], including digital options to widen
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patient choice and target inequality; test an NHS programme
supporting low calorie diets for people living with obesity and
type 2 diabetes, to try to achieve remission of type 2 diabetes
through weight loss; and to expand nutritional education for
health care professionals and trainees [34]. Many other coun-
tries are also considering or adopting diabetes prevention
programmes.
In a recent paper, we described how in recent years there
has been an increase in understanding of how to support peo-
ple make sustainable lifestyle changes, particularly dietary
[35•]. We further argued that such knowledge could be collat-
ed into a leaflet that could be easily explained and given to
patients in many clinical settings (primary or secondary care)
so that more health care professionals can give specific, ac-
tionable, evidenced-based advice that is consistent and easily
digestible. We proposed that this simple leaflet, an extension
of the ‘top ten tips’ concept [36], could detail a range of op-
tions, from simple dietary changes to more-intensive options.
We were also careful to stress that such advice should always
be given in an empathetic manner, as language really does
matter when health care professions engage people living with
obesity [37]. Of course, such work would need to be carefully
audited or researched and could be improved over time.
There are also excellent online resources for weight man-
agement that can be accessed, such as that available via the
NHS website [38, 39].
Finally, in a separate paper, we stressed that for many die-
tary changes to be sustained, patients should be encouraged to
retrain their palates towards healthier, equally enjoyable,
foods [40]. In other words, people must be told that positive
dietary changes can take a little time to embed, and that per-
severance is needed, but that the rewards are worthwhile. Not
making such points represents a missed opportunity.
Activity also Matters
Simpler messages should be usefully extended to activity tips.
Here, people need to be told it is rarely possible to achieve
weight loss by activity alone and that dietary improvements
are often pivotal and should be started first or in conjunction.
That said, activity helps lessen weight regain and most people
can be encouraged to be more active, but once again, the
messaging needs to be clearer and simple. For example, one
piece of advice would be to walk more as 10 mins extra walk-
ing can achieve 1000 extra steps per day, helpful to many who
are currently sedentary. Of course, for activity to benefit long-
term, it needs to be sustained over time, and so the main
concept is for people to find something they enjoy and try to
form new habits along these lines. As the lockdown eases, it is
hoped that activity levels will climb to slow population-wide
weight gain.
Conclusion
It is overwhelmingly clear that obesity (or excess ectopic fat)
is an important and major risk factor for adverse COVID-19
outcomes across many ethnicities. Future evidence is unlikely
to change this stark conclusion. Consequently, obesity be-
comes a strong ‘upstream’ risk factor not just for many
chronic diseases but also for an acute viral pandemic that,
sadly, continues to impact across the world, leaving consider-
able morbidity and mortality in its wake. Furthermore, in
many places, the indirect consequence of the pandemic (wors-
ening diets and less activity) will be increasing obesity prev-
alence, perhaps most manifest in those most at risk. Such
changes will fuel even more obesity-related diseases, further
stretching health services internationally. It is therefore impor-
tant that health systems around the world meet this challenge
by upscaling emphasis on and investments in obesity preven-
tion and treatments.
Recent successful interventions in weight management
need to be extended and offered to many more people at risk.
In addition, new, simpler, innovative ways to spread evidence-
based dietary or activity messages should also be examined as
many people with risk factors are not currently receiving ad-
vice. If ever there was a time to improve obesity prevention
and management, it is now.
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